Pivotal bioVenture Partners Investment Advisor LLC
Pivotal bioVenture Partners Investment Advisor LLC reported 13 holdings worth US$308M as of Jun 30, 2026 (Form 13F)
As of Jun 30, 2026 · Filed Aug 13, 2026
Pivotal bioVenture Partners Investment Advisor LLC reported 13 holdings worth US$308M as of Jun 30, 2026. Largest: Vaxcyte, Inc., Arcutis Biotherapeutics, Inc. and Trevi Therapeutics, Inc. Filed Aug 13, 2026 (Form 13F).
- Holdings
- 13
- Value as reported
- US$308M
The filing in full
| Company | Shares | Value as reported | % of portfolio |
|---|---|---|---|
| Vaxcyte, Inc. | 1.43M | US$82.9M | 26.9% |
| Arcutis Biotherapeutics, Inc. | 1.27M | US$33.2M | 10.8% |
| Trevi Therapeutics, Inc. | 1.74M | US$32.5M | 10.6% |
| Avalyn Pharma Inc. | 967K | US$31.8M | 10.3% |
| Evommune, Inc. | 1.93M | US$25.6M | 8.3% |
| Maplight Therapeutics, Inc. | 611K | US$21.9M | 7.1% |
| Bioage Labs, Inc. | 653K | US$16M | 5.2% |
| Immunome, Inc. | 733K | US$15.5M | 5.0% |
| Zenas Biopharma, Inc. | 491K | US$12.5M | 4.0% |
| Avalo Therapeutics, Inc. | 434K | US$8.02M | 2.6% |
| Rallybio Corporation | 301K | US$4.81M | 1.6% |
| Recursion Pharmaceuticals, Inc. | 596K | US$2.19M | 0.71% |
| Bolt Biotherapeutics, Inc. | 0 | US$0 | 0.00% |